Clazakizumab: Difference between revisions
m →Cancer: Results due June 2010 |
→Cancer: Results from 124 non small cell lung cancer (NSCLC) patients were favourable (eg. 1/10th the weight loss).<ref> |
||
| Line 36: | Line 36: | ||
A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.<ref>http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32916 "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer." 2009</ref> |
A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.<ref>http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32916 "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer." 2009</ref> |
||
A phase II trial for advanced cancer is due to end in Oct 2009.<ref>http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"</ref> Results due June 2010<ref>http://www.xconomy.com/seattle/2010/05/13/alder-seeks-to-treat-cancer-patients-in-a-radical-way-fighting-inflammation-not-tumors/?single_page=true </ref>. |
A phase II trial for advanced cancer is due to end in Oct 2009.<ref>http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"</ref> Results due June 2010<ref>http://www.xconomy.com/seattle/2010/05/13/alder-seeks-to-treat-cancer-patients-in-a-radical-way-fighting-inflammation-not-tumors/?single_page=true </ref>. Results from 124 non small cell lung cancer (NSCLC) patients were favourable (eg. 1/10th the weight loss).<ref>{{cite web|url=http://www.empr.com/phase-2a-study-of-ald518-for-treatment-of-non-small-cell-lung-cancer-nsclc-symptoms/article/171887/ |title=Phase 2a study of ALD518 for treatment of non small cell lung cancer (NSCLC) symptoms |date=June 2010 }}</ref> |
||
===Rheumatoid arthritis=== |
===Rheumatoid arthritis=== |
||
Revision as of 12:18, 15 June 2010
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | IL-6 |
| Clinical data | |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
ALD518 a humanized monoclonal antibody against interleukin-6. It is an investigational drug for cancer and rheumatoid arthritis due to its anti-inflamatory properties.
The relatively long half life of about 30 days should allow less frequent and subcutaneous injections.[1]
It is made using yeast cells rather than the standard Chinese hamster ovary cells.[1]
Clinical trials
Cancer
A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.[2]
A phase II trial for advanced cancer is due to end in Oct 2009.[3] Results due June 2010[4]. Results from 124 non small cell lung cancer (NSCLC) patients were favourable (eg. 1/10th the weight loss).[5]
Rheumatoid arthritis
The Phase IIa trial for rheumatoid arthritis[6] has completed with promising results leading to a licencing deal allowing phase III trials.[7] The results are to be presented in June 2010 at the European League Against Rheumatism (EULAR) meeting in Rome.[8]
References
- ^ a b http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/
- ^ http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32916 "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer." 2009
- ^ http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"
- ^ http://www.xconomy.com/seattle/2010/05/13/alder-seeks-to-treat-cancer-patients-in-a-radical-way-fighting-inflammation-not-tumors/?single_page=true
- ^ "Phase 2a study of ALD518 for treatment of non small cell lung cancer (NSCLC) symptoms". June 2010.
- ^ http://clinicaltrials.gov/ct2/show/NCT00867516
- ^ http://www.smartbrief.com/news/aanp/industryBW-detail.jsp?id=9279E59B-9E2A-4823-9476-17782B175A34 "Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic" 10 Nov 2009
- ^ http://www.xconomy.com/seattle/2010/03/19/innovation-northwest-wrapup-alder-tekmira-acucela-other-emerging-little-biotechs/
External links
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |